Ireland - English - HPRA (Health Products Regulatory Authority)

wilcox laboratories limited - digitoxin -

Australia - English - Department of Health (Therapeutic Goods Administration)

colestipol hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

quinine bisulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinine bisulfate heptahydrate, quantity: 300 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; carnauba wax; magnesium stearate; lactose monohydrate; colloidal anhydrous silica; purified talc; microcrystalline cellulose; povidone; titanium dioxide; hypromellose; macrogol 4000 - treatment of malaria due to strains of p. falciparum resistant to chloroquine and the related 4-aminoquinolines.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - colestipol hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - colestipol hydrochloride 5 g - granules for oral suspension - 5 g - active: colestipol hydrochloride 5 g - colestid is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol and low-density lipoprotein (ldl) cholesterol in patients with primary hypercholesterolaemia (elevated low density lipoproteins (ldl) cholesterol) who do not respond adequately to diet and to reduce the risks of atherosclerotic coronary artery disease and myocardial infarction. it may be used as the sole agent or in combination with additional lipid lowering agents. when compared to conventional measures, intensive lipid-lowering combination therapy, which included colestid plus either niacin or lovastatin, significantly reduced the frequency of progression and increased the frequency of regression of coronary atherosclerotic lesions in patients with, or at risk for, symptomatic coronary artery disease